{"DataElement":{"publicId":"2736109","version":"2","preferredName":"Adverse Event Discontinue Therapeutic Procedure Yes No Indicator","preferredDefinition":"A yes/no indicator whether there was a permanent or temporary cessation in the administration of a therapeutic agent or procedure to produce an effect that is intended to alter or stop a pathologic process as a result of any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure.","longName":"AE_DXD_TX_IND2","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"2736098","version":"1","preferredName":"Adverse Event Discontinue Therapeutic Procedure","preferredDefinition":"information related to the permanent or temporary cessation of the action or administration of therapeutic agents or procedures to produce an effect that is intended to alter or stop a pathologic process as a result of any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure.","longName":"AE_DXD_TX","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2235992","version":"1","preferredName":"Adverse Event","preferredDefinition":"Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.","longName":"C41331","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-74E9-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-15","modifiedBy":"ONEDATA","dateModified":"2005-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2736096","version":"1","preferredName":"Discontinued Therapeutic Procedure","preferredDefinition":"Discontinued; stopped permanently or temporarily.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25484:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"48D03560-937B-1C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-19","modifiedBy":"ONEDATA","dateModified":"2008-03-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"48D03560-938C-1C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857180","version":"1","longName":"Type of Category","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812086","version":"1","longName":"Restorative","context":"NIDCR"},{"publicId":"2812085","version":"1","longName":"Preventive","context":"NIDCR"}]},{"publicId":"2857182","version":"1","longName":"Protocol Forms","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812039","version":"1","longName":"PEARL","context":"NIDCR"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4442461","version":"1","longName":"Content for Review","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"4442571","version":"1","longName":"CDEs for Review","context":"NIDCR"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Treatment discontinued","type":"Preferred Question Text","description":"Treatment discontinued","url":null,"context":"NIDCR"},{"name":"CRF Text1","type":"Alternate Question Text","description":"AE led to discontinuation of Pembrolizumab","url":null,"context":"NRG"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Was chemotherapy discontinued during this reporting period due to chemotherapy adverse events?","url":null,"context":"Alliance"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Was the first-line chemotherapy discontinued during this reporting period?","url":null,"context":"Alliance"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Was second- or subsequent-line chemotherapy or other systemic therapy discontinued during this reporting period due to adverse events related to those medications?","url":null,"context":"Alliance"},{"name":"NRG_CRF Text 1","type":"Alternate Question Text","description":"AE led to discontinuation of Durvalumab","url":null,"context":"NRG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Was chemotherapy dose discontinued prior to completion?","url":null,"context":"COG"},{"name":"NRG_CRF Text 3","type":"Alternate Question Text","description":"AE led to discontinuation of Durvalumab/Cetuximab","url":null,"context":"NRG"},{"name":"OPEN Form","type":"Alternate Question Text","description":"Did the patient discontinue treatment due to adverse events?","url":null,"context":"ECOG-ACRIN"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Was second- or subsequent-line systemic therapy discontinued during this reporting period due to adverse events related to those medications?","url":null,"context":"Alliance"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Was the first-line systemic therapy discontinued during this reporting period?","url":null,"context":"Alliance"},{"name":"CRF TEXT7","type":"Alternate Question Text","description":"AE led to discontinuation of Abiraterone","url":null,"context":"NRG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Was gilteritinib permanently discontinued due to toxicity during this reporting period?","url":null,"context":"COG"}],"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"06325867-2894-C080-E050-BB89AD436B2D","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-10-24","modifiedBy":"LEEW","dateModified":"2019-11-19","changeDescription":"10/24/14 CDE versioned to use Standard Indicator VD. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}